Paydirt
CH
Insider

Christopher Hite

EVP & Chairman, Partnering

Christopher Hite (EVP & Chairman, Partnering) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Royalty Pharma plc (RPRX). The largest single filing was $8.2M of RPRX (150,000 sh across 2 lots, as filed), executed Jun 23.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$21.5M
shares × price, as filed
Last traded
Aug 18
Filed Aug 19

Median ADV $206.7M across their filed names

Open performance
Volume by month
$8.2M$4.1M$0Oct 2024Apr 2025Oct 2025Apr 2026Jun 2026 · sells $8.2MJul 2026 · sells $7.3MAug 2026 · sells $6.0M
Buys $0 Sells $21.5M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 3 filings

Sector per market data · by filing · past 12 months

Most traded names
RPRX Royalty Pharma plc RPRX · 0 buys · 3 sells 3 filings
Recent filings
RPRXSALE Royalty Pharma plc View filing → $6.0M
100,000 sh × $59.97
Exec Aug 18
Filed Aug 19 · 4:20 PM ET
RPRXSALE Royalty Pharma plc View filing → $7.3M
129,400 sh across 3 lots
Exec Jun 30
Filed Jul 2 · 4:08 PM ET
RPRXSALE Royalty Pharma plc View filing → $8.2M
150,000 sh across 2 lots
Exec Jun 23
Filed Jun 25 · 5:30 PM ET